154 related articles for article (PubMed ID: 37906371)
21. Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls.
Ferguson LD; Molenberghs G; Verbeke G; Rahimi K; Rao S; McInnes IB; McMurray JJV; Sattar N; Conrad N
Lancet Rheumatol; 2024 Mar; 6(3):e156-e167. PubMed ID: 38383089
[TBL] [Abstract][Full Text] [Related]
22. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003).
Lioté F; Lancrenon S; Lanz S; Guggenbuhl P; Lambert C; Saraux A; Chiarelli P; Delva C; Aubert JP; Ea HK
Joint Bone Spine; 2012 Oct; 79(5):464-70. PubMed ID: 22281230
[TBL] [Abstract][Full Text] [Related]
23. The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.
Yokose C; McCormick N; Abhishek A; Dalbeth N; Pascart T; Lioté F; Gaffo A; FitzGerald J; Terkeltaub R; Sise ME; Januzzi JL; Wexler DJ; Choi HK
Nat Rev Rheumatol; 2024 Apr; 20(4):216-231. PubMed ID: 38472344
[TBL] [Abstract][Full Text] [Related]
24. Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey.
Pascart T; Norberciak L; Ea HK; Guggenbuhl P; Lioté F
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):986-992. PubMed ID: 30022604
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Hu S; Sun M; Li M; Xue X; Terkeltaub R; Wang C; Wang M; Lu J; Ran Z; Li H; Ji A; Sun W; Li X; He Y; Liu Z; Zhang H; Wang X; Ji X; Dalbeth N; Li C
Rheumatology (Oxford); 2023 Jul; 62(7):2435-2443. PubMed ID: 36409036
[TBL] [Abstract][Full Text] [Related]
26. Risk factors of urinary calculi in men with gout.
Cao Y; Han X; Wang X; Zhang Y; Xiao H; Zeng X
Clin Rheumatol; 2022 Oct; 41(10):3143-3150. PubMed ID: 35739406
[TBL] [Abstract][Full Text] [Related]
27. Comorbidities in patients with gout.
Ichikawa N; Taniguchi A; Urano W; Nakajima A; Yamanaka H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1045-50. PubMed ID: 22132955
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study.
He Y; Xue X; Dalbeth N; Terkeltaub R; Chen Y; Yan F; Pang L; Li X; Yuan X; Cheng X; Li C; Sun M
Arthritis Care Res (Hoboken); 2024 Jan; 76(1):131-139. PubMed ID: 37553607
[TBL] [Abstract][Full Text] [Related]
29. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
30. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.
Wei J; Choi HK; Dalbeth N; Li X; Li C; Zeng C; Lei G; Zhang Y
JAMA Netw Open; 2023 Aug; 6(8):e2330885. PubMed ID: 37624597
[TBL] [Abstract][Full Text] [Related]
31. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.
Halpern R; Fuldeore MJ; Mody RR; Patel PA; Mikuls TR
J Clin Rheumatol; 2009 Feb; 15(1):3-7. PubMed ID: 19125135
[TBL] [Abstract][Full Text] [Related]
32. Demographic, clinical characteristics and cardiovascular disease burden in a Portuguese cohort of older chronic kidney disease patients.
Lascasas JMSS; Fonseca I; Malheiro J; Santos S; Campos A; Castro A; Moreira C; Correia S; Beirão I; Lobato L; Cabrita A
J Bras Nefrol; 2019; 41(1):29-37. PubMed ID: 31063177
[TBL] [Abstract][Full Text] [Related]
33. Medications for gout and its comorbidities: mutual benefits?
Yoshida K; Choi HK; Solomon DH
Curr Opin Rheumatol; 2021 Mar; 33(2):145-154. PubMed ID: 33399398
[TBL] [Abstract][Full Text] [Related]
34. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare.
Pascart T; Grandjean A; Capon B; Legrand J; Namane N; Ducoulombier V; Motte M; Vandecandelaere M; Luraschi H; Godart C; Houvenagel E; Norberciak L; Budzik JF
Arthritis Res Ther; 2018 Sep; 20(1):210. PubMed ID: 30223875
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of early- and late-onset gout: A cross-sectional observational study from a Chinese gout clinic.
Zhang B; Fang W; Zeng X; Zhang Y; Ma Y; Sheng F; Zhang X
Medicine (Baltimore); 2016 Nov; 95(47):e5425. PubMed ID: 27893683
[TBL] [Abstract][Full Text] [Related]
36. Risk of gout flares after COVID-19 vaccination: A case-crossover study.
Li H; Dalbeth N; Wallace ZS; Sparks JA; Li X; Zeng C; Wang Y; Xie D; Lei G; Wei J; Zhang Y
Semin Arthritis Rheum; 2022 Oct; 56():152059. PubMed ID: 35797765
[TBL] [Abstract][Full Text] [Related]
37. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
38. Seasonality of gout in Korea: a multicenter study.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo H; Choi SJ; Lee JS; Shin K; Jun JB; Baek HJ
J Korean Med Sci; 2015 Mar; 30(3):240-4. PubMed ID: 25729244
[TBL] [Abstract][Full Text] [Related]
39. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.
Bardin T; Richette P
BMC Med; 2017 Jul; 15(1):123. PubMed ID: 28669352
[TBL] [Abstract][Full Text] [Related]
40. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
